140 related articles for article (PubMed ID: 10547605)
1. Pathological features of glycogen storage disease type II highlighted in the knockout mouse model.
Bijvoet AG; Van Hirtum H; Vermey M; Van Leenen D; Van Der Ploeg AT; Mooi WJ; Reuser AJ
J Pathol; 1999 Nov; 189(3):416-24. PubMed ID: 10547605
[TBL] [Abstract][Full Text] [Related]
2. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT
Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
[TBL] [Abstract][Full Text] [Related]
3. Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease.
Rucker M; Fraites TJ; Porvasnik SL; Lewis MA; Zolotukhin I; Cloutier DA; Byrne BJ
Development; 2004 Jun; 131(12):3007-19. PubMed ID: 15169761
[TBL] [Abstract][Full Text] [Related]
4. Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse.
Kamphoven JH; de Ruiter MM; Winkel LP; Van den Hout HM; Bijman J; De Zeeuw CI; Hoeve HL; Van Zanten BA; Van der Ploeg AT; Reuser AJ
Neurobiol Dis; 2004 Jun; 16(1):14-20. PubMed ID: 15207257
[TBL] [Abstract][Full Text] [Related]
5. [A retrospective study of six patients with late-onset Pompe disease].
Saux A; Laforet P; Pagès AM; Figarella-Branger D; Pellissier JF; Pagès M; Labauge P
Rev Neurol (Paris); 2008 Apr; 164(4):336-42. PubMed ID: 18439925
[TBL] [Abstract][Full Text] [Related]
6. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
[TBL] [Abstract][Full Text] [Related]
7. Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II.
Douillard-Guilloux G; Raben N; Takikita S; Batista L; Caillaud C; Richard E
Hum Mol Genet; 2008 Dec; 17(24):3876-86. PubMed ID: 18782850
[TBL] [Abstract][Full Text] [Related]
8. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
[TBL] [Abstract][Full Text] [Related]
9. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme.
Raben N; Jatkar T; Lee A; Lu N; Dwivedi S; Nagaraju K; Plotz PH
Mol Ther; 2002 Nov; 6(5):601-8. PubMed ID: 12409258
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II.
Ravaglia S; Danesino C; Pichiecchio A; Repetto A; Poloni GU; Rossi M; Fratino P; Moglia A; Costa A
Adv Ther; 2008 Aug; 25(8):820-9. PubMed ID: 18704279
[TBL] [Abstract][Full Text] [Related]
11. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors.
Mah C; Cresawn KO; Fraites TJ; Pacak CA; Lewis MA; Zolotukhin I; Byrne BJ
Gene Ther; 2005 Sep; 12(18):1405-9. PubMed ID: 15920463
[TBL] [Abstract][Full Text] [Related]
12. Immortalization of murine muscle cells from lysosomal alpha-glucosidase deficient mice: a new tool to study pathophysiology and assess therapeutic strategies for Pompe disease.
Douillard-Guilloux G; Mouly V; Caillaud C; Richard E
Biochem Biophys Res Commun; 2009 Oct; 388(2):333-8. PubMed ID: 19665008
[TBL] [Abstract][Full Text] [Related]
13. Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model.
Taksir TV; Griffiths D; Johnson J; Ryan S; Shihabuddin LS; Thurberg BL
J Histochem Cytochem; 2007 Oct; 55(10):991-8. PubMed ID: 17510371
[TBL] [Abstract][Full Text] [Related]
14. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
[TBL] [Abstract][Full Text] [Related]
15. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease.
Douillard-Guilloux G; Richard E; Batista L; Caillaud C
J Gene Med; 2009 Apr; 11(4):279-87. PubMed ID: 19263466
[TBL] [Abstract][Full Text] [Related]
16. Impaired performance of skeletal muscle in alpha-glucosidase knockout mice.
Hesselink RP; Gorselink M; Schaart G; Wagenmakers AJ; Kamphoven J; Reuser AJ; Van Der Vusse GJ; Drost MR
Muscle Nerve; 2002 Jun; 25(6):873-83. PubMed ID: 12115977
[TBL] [Abstract][Full Text] [Related]
17. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
[TBL] [Abstract][Full Text] [Related]
18. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
Hawes ML; Kennedy W; O'Callaghan MW; Thurberg BL
Mol Genet Metab; 2007 Aug; 91(4):343-51. PubMed ID: 17572127
[TBL] [Abstract][Full Text] [Related]
19. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
[TBL] [Abstract][Full Text] [Related]
20. Age-related morphological changes in skeletal muscle cells of acid alpha-glucosidase knockout mice.
Hesselink RP; Schaart G; Wagenmakers AJ; Drost MR; van der Vusse GJ
Muscle Nerve; 2006 Apr; 33(4):505-13. PubMed ID: 16372321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
